Today's Date: January 17, 2021
Tractor Supply Company Appoints Joy Brown to Its Board of Directors   •   Feinstein Institutes Awarded More Than $4M to Research Perinatal Depression   •   Columbia Care Receives Provisional License for Adult Use at its Patriot Care Dispensary in Downtown Boston   •   BET Announces Its Multiplatform Programming Strategy for Inauguration 2021   •   360WiSE MEDiA Helps In Social Justice With Digitally Amplifying The Voice For Social, Economic, and Environmental Change With Th   •   BET to Air Mega Night of Tyler Perry Must-Watch Originals With the Return of “Tyler Perry’s The Oval” and the   •   Rivers Casino Philadelphia Resumes Indoor Dining on Saturday, Jan. 16, at Noon   •   Newkirk Zwagerman, PLC and Bogas & Koncius, PC: Michigan State University's Women's Varsity Swimming and Diving Team Files T   •   Connecticut Water Files Application With Connecticut Public Utilities Regulatory Authority (PURA) to Amend Rates   •   My Eyelab is Now in Michigan: New Store in the Saginaw Area   •   NAELA Celebrates Passage of Latest COVID-19 Relief Package   •   MLK Jr. oratory competitions go virtual, allowing kids to send messages of hope to a nation in distress   •   Speech from the Governor General and Commander-in-Chief of Canada   •   American Lending Center Supports Small and Minority-Owned Businesses in Second Round PPP   •   San Carlos Apache Tribe Sues US Forest Service to Stop Resolution Copper Mine   •   Health Care of South Florida opens a new office in Broward County   •   Statement by Minister Chagger on Raoul Wallenberg Day   •   Unmet Need for Afterschool Programs Skyrockets in the Black Community, With Four Million Black Children Without the Access to Af   •   Singer-Songwriter Baby Yors Drops Single & Video for Sex-Fueled Dance Anthem "Like A Gun"   •   Birks Group Presents Its FY2021 Holiday Period Sales Results
Bookmark and Share

Solace Therapeutics Announces that Regional Urology Enrolls First Patient in US Pivotal Clinical Trial, using New Office-Based T

SHREVEPORT, La. , December 01 /Businesswire/ - Regional Urology, has enrolled their first patient in the VESAIR Clinical Trial. The VESAIR Clinical Trial is being conducted in several distinguished clinics throughout the US to test the safety and efficacy of the Vesair Bladder Control Balloon procedure.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201201005763/en/

(Photo: Business Wire)

(Photo: Business Wire)

“I am delighted to be participating in the VESAIR Clinical Trial. SUI is not life-threatening, but if left untreated, it can greatly diminish a woman’s Quality of Life. Having a non-surgical option would be a great alternative for the nearly 1 in 2 women over the age of 50, who suffer from this condition” said Kevin Cline, MD, Principal Investigator for the VESAIR Clinical Trial.

About Stress Urinary Incontinence and the Vesair Bladder Control System

Women with Stress Urinary Incontinence(SUI) typically experience sudden increases in bladder pressure during physical movement, for example coughing, laughing, sneezing, or during exercise. When this increased bladder pressure exceeds the ability of the urethral sphincter to withstand pressure, leakage occurs. Unlike currently available SUI treatments that focus on improving the urethral closure force, the Vesair Bladder Control System is designed to reduce rapid increases in bladder pressure through the placement of a compressible air-filled balloon in the bladder. The balloon acts like a “shock-absorber” to slow rapid changes in pressure and reduce leakage. The uninflated balloon is placed into the bladder through the urethra and subsequently inflated. Balloon placement is performed during an in-office procedure that does not require anesthesia. When necessary, the balloon is deflated and removed in a similar in-office procedure. Most women manage their SUI with absorbent pads and are reluctant to undergo surgery for a variety of reasons. To learn more about the VESAIR Clinical Trial visit; www.laughwithoutleaks.com.

About Solace Therapeutics, Inc.

Solace Therapeutics is an emerging women’s health company focused on a new office-based treatment for symptoms of female SUI. SUI is the most prevalent form of incontinence among women and affects an estimated 15 million adult women in the U.S. These women choose to manage their SUI by utilizing absorbent products such as protective pads versus seeking medical help. Solace is dedicated to improving the quality of life for women whose daily life is disrupted by their incontinence. Please visit www.solacetx.com to learn more about the company and review results from the first two clinical trials.


STORY TAGS: Photo/Multimedia, Product/Service, United States, North America, Louisiana, Medical Supplies, Health, Medical Devices, Consumer, Women, General Health, Clinical Trials,

Video

White House Live Stream
LIVE VIDEO EVERY SATURDAY
alsharpton Rev. Al Sharpton
9 to 11 am EST
jjackson Rev. Jesse Jackson
10 to noon CST


Video

LIVE BROADCASTS
Sounds Make the News ®
WAOK-Urban
Atlanta - WAOK-Urban
KPFA-Progressive
Berkley / San Francisco - KPFA-Progressive
WVON-Urban
Chicago - WVON-Urban
KJLH - Urban
Los Angeles - KJLH - Urban
WKDM-Mandarin Chinese
New York - WKDM-Mandarin Chinese
WADO-Spanish
New York - WADO-Spanish
WBAI - Progressive
New York - WBAI - Progressive
WOL-Urban
Washington - WOL-Urban

Listen to United Natiosns News